arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Eloxx Pharmaceuticals, Inc.

ELOX
$17.88 ▲ +0.42 (+2.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Eloxx Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $46.0M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC 80.0%
FCF / Share $-5.58
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.04
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-17.05M
↑ +52.7%
FCF / Share Free cash flow per share
$-5.58
↑ +62.1%
Long-Term Debt Long-term obligations
$1.00M
↓ -91.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health
63
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 27 years · 67 quarters